Dr. Chen Saijuan
Director, Shanghai Institute of Hematology; Chief Physician; Professor; Academician of the Chinese Academy of Engineering
Where they practice, who they consult.
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Institute of Hematology, Shanghai
- 40+ years in leukemia research and clinical care
- English, Mandarin
What they personally lead.
Training and recognition
Co-developed with Dr. Wang Zhenyi and Dr. Chen Zhu the all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) regimen that converted APL from a fatal disease into a curable one with cure rates above 90% — recognized internationally with the Szent-Györgyi Prize for Progress in Cancer Research; Academician of the Chinese Academy of Engineering; publications in NEJM, Blood, PNAS
What to expect
Ruijin remains a global reference center for APL. Patients with newly diagnosed or relapsed APL benefit from the institutional protocol experience; for non-APL leukemias the Ruijin team also runs clinical trials.
Check the public record
Look up publications, citations, and academic profile on independent platforms before reaching out.
Results are automated searches and may include other individuals with similar names.
Ask the AI or request a coordinator.
The AI can compare Chen Saijuan's background to other specialists in Shanghai. A coordinator can confirm appointment availability and English-language support.
Information is provided for reference only and may not reflect current conditions. Verify directly with the hospital before making decisions.